Roth Capital analyst Debjit Chattopadhyay weighed in today with a favorable report on Sarepta Therapeutics Inc (NASDAQ:SRPT), after the company announced the completion of its …
Global X Funds (NYSEARCA:GREK) plummeted -17% in pre-market trading to $9.75 after the European Central bank announced it would not expand Greece’s emergency …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the completion of the rolling submission of a New Drug Application (NDA) …
RBC Capital analyst Simos Simeonidis weighed in today on two biotech stocks, Sarepta Therapeutics Inc (NASDAQ:SRPT) and PTC Therapeutics, Inc. (NASDAQ:PTCT), following the release of the FDA Draft Document …
In a research report released Sunday, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics Inc. (NASDAQ:SRPT) with a price …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, granted an equity award today to Rachel Chan. The award was previously approved by …
Sarepta Therapeutics Inc (NASDAQ:SRPT) price target has been raised by research analyst Stephen Brozak at WBB Securities. The new price target now stands …
Roth Capital analyst Debjit Chattopadhyay came out today with a favorable note on Sarepta Therapeutics Inc (NASDAQ:SRPT), following a negative article published in the Wall Street Journal …
Sarepta Therapeutics Inc (NASDAQ:SRPT) Sarepta Therapeutics stock is having an amazing day in the market today after an announcement was made about a …
On May 19, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced plans to complete a New Drug Application (NDA) for eteplirsen, Sarepta’s lead product candidate. SRPT …
